Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.86 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.76 |
| ▸ | LMNA | P02545 | 1/20 | 0.76 |
| ▸ | MAPT | P10636 | 1/20 | 0.76 |
| ▸ | ATM | Q13315 | 1/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.76 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.76 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.67 |
| ▸ | RELA | Q04206 | 2/20 | 0.66 |
| ▸ | PDE4A | P27815 | 1/20 | 0.65 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.65 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.65 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.65 |
| ▸ | JUN | P05412 | 1/20 | 0.65 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.65 |
| ▸ | CTSL | P07711 | 1/20 | 0.64 |
| ▸ | CTSB | P07858 | 1/20 | 0.64 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.64 |
| ▸ | CA1 | P00915 | 1/20 | 0.64 |
| ▸ | CA2 | P00918 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7099538 | 1.00 | ABCG2 (0.86) | ABCG2KDM4ELMNAMAPTATM | |
| SCHEMBL29394843 | 1.00 | ABCG2 (0.86) | ABCG2KDM4ELMNAMAPTATM | |
| SCHEMBL7185006 | 0.92 | ABCG2 (0.97) | ABCG2KDM4ELMNAMAPTATM | |
| SCHEMBL7185011 | 0.92 | ABCG2 (0.97) | ABCG2KDM4ELMNAMAPTATM | |
| SCHEMBL7100049 | 0.89 | TNFRSF1A (0.84) | ABCG2KDM4ELMNAMAPTATM | |
| SCHEMBL7192054 | 0.89 | TNFRSF1A (0.84) | ABCG2KDM4ELMNAMAPTATM | |
| SCHEMBL6352780 | 0.88 | ABCG2 (0.89) | ABCG2KDM4ELMNAMAPTATM | |
| SCHEMBL6352783 | 0.88 | ABCG2 (0.89) | ABCG2KDM4ELMNAMAPTATM | |
| SCHEMBL30307319 | 0.88 | ABCG2 (0.89) | ABCG2KDM4ELMNAMAPTATM | |
| SCHEMBL19182869 | 0.86 | LMNA (1.00) | ABCG2KDM4ELMNAMAPTATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250376441-A1 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | UNIV YONSEI IACF (KR) | 2025-12-11 | — | — | US | disclosed |
| US-12447137-B2 | Composition for prevention, amelioration, or treatment of cancer | EWHA University—Industry Collaboration Foundation (KR) | 2025-10-21 | — | — | US | disclosed |
| US-20220226263-A1 | Composition for Prevention, Amelioration, or Treatment of Cancer | CHA UNIVERSITY INDUSTRY-ACADEMIC COOOPERATION FOUNDATION (KR) | 2022-07-21 | — | — | US | disclosed |
| EP-3977988-A1 | COMPOSITION FOR PREVENTION, AMELIORATION, OR TREATMENT OF CANCER | Ewha University-Industry Collaboration Foundation (KR) | 2022-04-06 | — | — | EP | disclosed |
| WO-2020242201-A1 | COMPOSITION FOR PREVENTION, AMELIORATION, OR TREATMENT OF CANCER | 이화여자대학교 산학협력단 | 2020-12-03 | — | — | WO | disclosed |
| WO-2020184998-A1 | COMPOSITION FOR PREVENTING, ALLEVIATING OR TREATING METABOLIC DISEASES | 연세대학교 산학협력단 | 2020-09-17 | — | — | WO | disclosed |
| US-20200190024-A1 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | CHA UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2020-06-18 | — | — | US | disclosed |
| US-20200190024-A1 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | CHA UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2020-06-18 | — | — | US | disclosed |
| EP-3626703-A1 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | Industry-Academic Cooperation Foundation, Yonsei University (KR) | 2020-03-25 | — | — | EP | disclosed |
| WO-2018212368-A1 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | 연세대학교 산학협력단 | 2018-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190024-A1 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | PRKAA1, PRKAA2, PRKAG1 | ABCG2 913/4885KDM4E 3574/4885LMNA 1969/4885 |
| US-20220226263-A1 | Composition for Prevention, Amelioration, or Treatment of Cancer | FABP2, FABP1, TSG101 | ABCG2 4190/4885KDM4E 4208/4885LMNA 1370/4885 |
| US-20250376441-A1 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | PRKAA1, PRKAA2, PRKAG1 | ABCG2 913/4885KDM4E 3574/4885LMNA 1969/4885 |
| US-12447137-B2 | Composition for prevention, amelioration, or treatment of cancer | GSTO1, FABP1, GSTK1 | ABCG2 3481/4885KDM4E 4179/4885LMNA 837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.